Progression-Free Survival and Molecular Features of Recurrent Intracranial Meningiomas: A Single-Center Retrospective Study

The Brain's Uninvited Guests: A Story of Recurrence

Imagine your brain is a bustling, high-security city. Sometimes, unwanted visitors called tumors move in. Most of these visitors are the "good" kind of troublemakers: they grow slowly, stay in one neighborhood, and usually leave when you ask them nicely (surgery). These are called meningiomas, and they are the most common type of primary brain tumor. For the vast majority, a simple surgery is like a security guard escorting them out, and the city goes back to normal.

But what happens when the guest doesn't just leave, but sneaks back in? That's the puzzle this study tackles. When a tumor returns, doctors need to know: Will it come back again? How fast? And is it more dangerous this time? To answer this, scientists look at two things: the "visual clues" (how the tumor looks under a microscope and where it is) and the "DNA clues" (the genetic instructions inside the tumor cells). This paper is like a detective report from a single hospital, trying to figure out which clues are the most reliable for predicting when a meningioma will decide to throw a second (or third) party.

The Detective Work: Tracking the Returnees

The researchers at Capital Medical University decided to look back at their own records, like flipping through a giant photo album from January 2019 to May 2024. They found 991 patients with meningiomas, but they were only interested in the 65 brave souls who had to go back for a second surgery because their tumors had returned. They wanted to see what made these specific tumors different from the ones that stayed away.

The "Who, What, and Where" of the Returnees
The group of 65 patients was a mix of ages, but most were in their 50s. Interestingly, while women usually get these tumors more often, the men in this group seemed to have a tougher time. The tumors were mostly found near the big "highways" of the brain (the venous sinuses), and about half of them had been completely removed the first time, while the other half were only partially scooped out.

The Clues That Predicted the Next Visit
The team played a game of "connect the dots" to see which factors predicted how long it would be before the tumor came back again (a time they call "Progression-Free Survival," or PFS).

• The Speedometer: They looked at a marker called Ki-67, which acts like a speedometer for how fast the tumor cells are dividing. The paper found that if the speedometer was high (10% or more), the tumor was much more likely to return quickly.
• The Neighborhood: Tumors that were tangled up with the brain's major veins (venous sinus involvement) were also more likely to come back sooner.
• The Grade: The "grade" is like a school report card for the tumor. Grade 1 is "good behavior," Grade 2 is "a bit rowdy," and Grade 3 is "very dangerous." The study confirmed that higher grades meant a shorter time before the next recurrence.

The Big Surprise: The Gender Gap
Here is the twist that the math revealed. When the researchers looked at all the clues together (age, tumor size, how much was removed, and the speedometer), one factor stood out as the only one that independently predicted a shorter time before the tumor returned: being male.

The study calculated that male patients had a "time ratio" of 0.646. In plain English, this means that, all else being equal, men in this group saw their tumors return significantly faster than women. While factors like the tumor's grade or the Ki-67 speedometer were important when looked at alone, they didn't hold up as the only cause when everything was weighed together. The paper suggests that being male is a strong, independent signal that the tumor might be more aggressive in its return.

The New "DNA Detective" Tool
The researchers also tried something newer: looking at the tumor's DNA. They took 30 of the tumors and ran a molecular test to see if there were hidden genetic glitches, like broken instructions (mutations) or missing pages in the genetic book (deletions).

They found that this molecular testing was a game-changer for some patients. There were a few tumors that looked "safe" (Grade 1 or 2) under the microscope, but their DNA told a different story. They had dangerous genetic markers (like TERT mutations or CDKN2A/B deletions) that forced the doctors to reclassify them as the dangerous Grade 3. It's like finding out a quiet neighbor actually has a secret identity as a master criminal. This suggests that for tumors that come back, checking the DNA might catch the dangerous ones that the microscope misses.

What Happened Next?
The study also tracked what happened after the second surgery. Some patients got radiation therapy, one joined a drug trial, and others just waited. The researchers noted that 13 patients had to go through multiple recurrences, with some needing a third or even fourth surgery. One patient even had the tumor spread to their lungs, which is very rare and serious.

The Bottom Line
This study doesn't claim to have solved the mystery of meningiomas forever. It's a single-center look at 65 patients, so it's a snapshot, not the whole movie. However, it strongly suggests that when a meningioma comes back, doctors should pay extra attention to the patient's sex (men may face a quicker return), the tumor's speedometer (Ki-67), and its location near veins. Most importantly, it shows that adding a DNA check to the standard microscope exam can reveal hidden dangers in tumors that look harmless, helping doctors treat the right patients with the right intensity. The paper concludes that while we still rely on the old-school visual clues, the new molecular tools are becoming essential for understanding these tricky, returning guests.